82499-60-3

Usage

Uses

Used in Pharmaceutical Industry:
((4-Bromobenzyl)oxy)acetic acid is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structure of drugs, enhancing their therapeutic properties and effectiveness.
Used in Chemical Industry:
((4-Bromobenzyl)oxy)acetic acid is used as a building block in the production of various organic compounds, contributing to the development of new chemical entities with potential applications in different fields.
Used in Research and Development:
((4-Bromobenzyl)oxy)acetic acid is used as a reagent in organic synthesis and in the research and development of new compounds with potential medicinal properties, facilitating the discovery and innovation of novel therapeutic agents.

InChI:InChI=1/C9H9BrO3/c10-8-3-1-7(2-4-8)5-13-6-9(11)12/h1-4H,5-6H2,(H,11,12)

Upstream product

• 256413-71-5 ethyl 2-(4-bromobenzyloxy)acetate 
• 64-69-7 Iodoacetic acid 
• 873-75-6 4-bromobenzenemethanol 
• 79-08-3 bromoacetic acid 
• 589-17-3 p-bromobenzyl chloride 
• 79-11-8 chloroacetic acid 
• 1454928-09-6 tert-butyl 2-((4-bromobenzyl)oxy)acetate 

Downstream Products

• 1454925-76-8 2-(4'-(((1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methoxy)methyl)-[1,1'-biphenyl]-3-yl)acetic acid 
• 1454928-11-0 3-(((4-bromobenzyl)oxy)methyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one 
• 1454928-12-1 ethyl 2-(4'-(((1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methoxy)methyl)-[1,1 '-biphenyl]-3-yl)acetate 
• 1454928-10-9 2-(2-((4-bromobenzyl)oxy)acetyl)-1-(4-(tert-butyl)benzyl)-N-ethylhydrazinecarboxamide 
• 943742-51-6 benzyl 3-(2-(4-bromobenzyloxy)acetamido)benzylcarbamate 

Relevant academic research and scientific papers

Glycerol conversion to high-value chemicals: The implication of unnatural α-amino acid syntheses using natural resources

Glycerol derivatives are an important class of compounds, which have great applications as basic structural building blocks in organic synthesis. O-Benzylglycerol was oxidised to produce a high-value compound in high yield using a NaOtBu-O2 system. Furthermore, the synthetic utility of the resulting product was demonstrated by its transformation into unnatural α-amino acids, thus showing the valorisation of glycerol biomass.

Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) to Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo

Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-Associated molecular patterns (PAMPs) and damage-Associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor B (NF-B) and mitogen-Activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-Activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

Practical preparation of benzyloxyacetic acids

An efficient and practical method for the preparation of benzyloxyacetic acids is described. The procedure involves the reaction of readily available chloroacetic acid with benzyl alcohol in the presence of powdered KOH providing a safer alternative to the known literature procedures, which completely eliminates the use of pyrophoric bases such as sodium hydride and sodium metal.

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

Design, Synthesis, and Testing of Potential Antisickling Agents. 4. Structure-Activity Relationships of Benzyloxy and Phenoxy Acids

In this paper we further establish the activity of two classes of small molecules, benzyloxy and phenoxy acids, as potent inhibitors of hemoglobin S (HbS) gelation.Structural modifications with a large number of each class confirm our earlier work that the highest activity is observed with compounds that contain dihalogenated aromatic rings with attached polar side chains.We have also found a halogenated aromatic malonic acid derivative to be quite active.Compounds reported in this paper are compared with other antigelling agents studied in our laboratory.Comments are made concerning the antigelling activity and binding sites of four derivatives and their effect on the allosteric mechanism of hemoglobin (Hb) function.